Posts Tagged ‘application’

Mar
06/10
WindSpring Announces Support for Apple’s iPhone, iPod touch and iPad
Last Updated on Friday, 5 March 2010 09:39
Written by editor
Saturday, March 6th, 2010
WindSpring, Inc., a leader in mobile data optimization technologies, today announced that DMTools™, the company’s software suite for mobile data optimization, now provides full interoperability with the Apple iPhone and iPad, including full support for iPhone SDK 3.2, OSX and XCode, Apple’s premiere OSX development environment. “The powerful data management tools WindSpring has created are essential to the development of the next generation of rich, powerful mobile applications and services,” said Tim Bajarin, president of Creative Strategies, a leading technology industry analysis and strategic planning firm. WindSpring’s DMTools is a complete set of software tools for seamlessly optimizing application data in mobile, embedded and other space-constrained environments. It includes tools for analyzing data and data performance, libraries for data compression, access and update, utilities for optimizing the performance aspects of compressed data, and SDKs for the predominant desktop and embedded OS/IDE environments. In addition, DMTools enables advanced functions such as search and update — capabilities not previously available with traditional compression solutions. “While the iPhone and iPad have led mobile application developers to push the boundaries of immersive and data-rich mobile applications, those devices still have only a fraction of the storage capacity of a PC,” said Tom Hunt, president and CEO of WindSpring. “WindSpring DMTools is the first tool set to optimize mobile application data on the device and make devicecommunications far more efficient.” www.windspring.com
Mar
06/10
eDr.Rx e-Prescribing Solution Will Support New iPad Device
Last Updated on Friday, 5 March 2010 09:37
Written by editor
Saturday, March 6th, 2010
Wayne Singer, President and CEO of eDr.Rx, announced recently that the company’s eDr.Rx e-prescription management application will support the new Apple iPad device when it is released in late March. Prospective clients will be able to securely sign up for eDr.Rx services through the iTunes App Store. eDr.Rx currently allows access with all browser-based form factors, including PCs, Tablet PCs, smart phones and PDAs, using either Windows and Mac operating systems. eDr.Rx is a Web-based electronic prescribing application that does not require dedicated hardware or software. Nothing beyond a high-speed Internet connection, including wireless, is required to access the application from multiple offices, home, or on-call. eDr.Rx includes work-flow support and connectivity features, drug interaction alerts and formularies from over 4,500 health plans, including Medicare Part D. The application can be used in conjunction with many practice management or EMR solutions. “The eDr.Rx system’s primary benefits are the workflow improvements it brings to providers. They can use the application anywhere and any time they have access to the Internet. We will continue to add to the number of mobile devices the application supports,” Singer explained. “Additionally, the allergy, drug and pregnancy interaction alerts enhance care and improve patient safety. We also offer our clients access to a feature called Your RxCard, which helps ensure their patients pay the lowest price possible for their prescriptions, which can enhance compliance. And, a very important feature is that the Medicare two percent bonus incentive for electronic prescribing covers the entire cost of our application and services,” Singer added. eDr.Rx accesses the Pharmacy Health Information Exchange™ operated by SureScripts®, facilitating the simple and secure transmission of prescription data to connected pharmacies and management of renewal requests. eDr.Rx clients also have access to RxHub®, a health plan repository of precise, patient-specific formularies for covered patients. In addition, an all-doctor drug history is automatically checked for drug interactions and duplicative therapies.